Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.

Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R.

Cancer. 2018 Oct 15;124(20):4080-4089. doi: 10.1002/cncr.31724. Epub 2018 Sep 11.

2.

GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.

Sheng X, Kong Y, Li Y, Zhang Q, Si L, Cui C, Chi Z, Tang B, Mao L, Lian B, Wang X, Yan X, Li S, Dai J, Guo J.

Eur J Cancer. 2016 Sep;65:156-63. doi: 10.1016/j.ejca.2016.06.019. Epub 2016 Aug 4.

PMID:
27498141
3.

Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.

Möller I, Murali R, Müller H, Wiesner T, Jackett LA, Scholz SL, Cosgarea I, van de Nes JA, Sucker A, Hillen U, Schilling B, Paschen A, Kutzner H, Rütten A, Böckers M, Scolyer RA, Schadendorf D, Griewank KG.

Mod Pathol. 2017 Mar;30(3):350-356. doi: 10.1038/modpathol.2016.201. Epub 2016 Dec 9.

4.

Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.

Psinakis F, Katseli A, Koutsandrea C, Frangia K, Florentin L, Apostolopoulou D, Dimakopoulou K, Papakonstantinou D, Georgopoulou E, Brouzas D.

Anticancer Res. 2017 Oct;37(10):5719-5726.

PMID:
28982892
5.

Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.

Koopmans AE, Vaarwater J, Paridaens D, Naus NC, Kilic E, de Klein A; Rotterdam Ocular Melanoma Study group.

Br J Cancer. 2013 Jul 23;109(2):493-6. doi: 10.1038/bjc.2013.299. Epub 2013 Jun 18.

6.

GNAQ and GNA11 mutations in uveal melanoma.

Shoushtari AN, Carvajal RD.

Melanoma Res. 2014 Dec;24(6):525-34. doi: 10.1097/CMR.0000000000000121. Review.

PMID:
25304237
7.

Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.

Lyu J, Wu Y, Li C, Wang R, Song H, Ren G, Guo W.

J Oral Pathol Med. 2016 Apr;45(4):295-301. doi: 10.1111/jop.12358. Epub 2015 Sep 24.

PMID:
26399561
8.

Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.

Staby KM, Gravdal K, Mørk SJ, Heegaard S, Vintermyr OK, Krohn J.

Acta Ophthalmol. 2018 Feb;96(1):31-38. doi: 10.1111/aos.13452. Epub 2017 Apr 26.

9.

Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi.

Bender RP, McGinniss MJ, Esmay P, Velazquez EF, Reimann JD.

Mod Pathol. 2013 Oct;26(10):1320-8. doi: 10.1038/modpathol.2013.77. Epub 2013 Apr 19.

10.

Genetic and clinico-pathologic analysis of metastatic uveal melanoma.

Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, Haydu LE, Asher M, Zimmer L, Hillen U, Thompson JF, Scolyer RA, Schadendorf D, Murali R.

Mod Pathol. 2014 Feb;27(2):175-83. doi: 10.1038/modpathol.2013.138. Epub 2013 Jul 26.

11.

The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.

Ominato J, Fukuchi T, Sato A, Yamaguchi N, Kobayashi K, Cho H, Oyama T, Ajioka Y.

Appl Immunohistochem Mol Morphol. 2018 Oct;26(9):658-663. doi: 10.1097/PAI.0000000000000505.

PMID:
28248732
12.

Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.

Metz CH, Scheulen M, Bornfeld N, Lohmann D, Zeschnigk M.

Cancer Med. 2013 Apr;2(2):208-15. doi: 10.1002/cam4.61. Epub 2013 Feb 14.

13.

Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.

Scholz SL, Möller I, Reis H, Süßkind D, van de Nes JAP, Leonardelli S, Schilling B, Livingstone E, Schimming T, Paschen A, Sucker A, Murali R, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3464-3470. doi: 10.1167/iovs.17-21838.

PMID:
28700778
14.

Mutations in GNA11 in uveal melanoma.

Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC.

N Engl J Med. 2010 Dec 2;363(23):2191-9. doi: 10.1056/NEJMoa1000584. Epub 2010 Nov 17.

15.

Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.

Xu X, Wei WB, Li B, Gao F, Zhang Z, Jonas JB.

PLoS One. 2014 Oct 3;9(10):e109699. doi: 10.1371/journal.pone.0109699. eCollection 2014.

16.

Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.

Ayturk UM, Couto JA, Hann S, Mulliken JB, Williams KL, Huang AY, Fishman SJ, Boyd TK, Kozakewich HP, Bischoff J, Greene AK, Warman ML.

Am J Hum Genet. 2016 Apr 7;98(4):789-95. doi: 10.1016/j.ajhg.2016.03.009. Erratum in: Am J Hum Genet. 2016 Jun 2;98 (6):1271.

17.

Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia.

Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H 3rd, Thakker RV.

N Engl J Med. 2013 Jun 27;368(26):2476-2486. doi: 10.1056/NEJMoa1300253.

18.
19.

Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes.

Bekers EM, Eijkelenboom A, Rombout P, van Zwam P, Mol S, Ruijter E, Scheijen B, Flucke U.

Diagn Pathol. 2019 Feb 8;14(1):15. doi: 10.1186/s13000-019-0787-3.

20.

The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.

Musi E, Ambrosini G, de Stanchina E, Schwartz GK.

Mol Cancer Ther. 2014 May;13(5):1044-53. doi: 10.1158/1535-7163.MCT-13-0550. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2250.

Supplemental Content

Support Center